Table 4.

Potential benefits and harms from tolvaptan treatment in ADPKD

Benefits	Harms
Slows kidney growth	Polyuria, pollakiuria, and nocturia
Slows eGFR decline	Thirst and fatigue
May delay need for renal replacement	Uric acid elevations (rarely gout)
Reduces pain, hematuria, stone, and urinary tract infection events	Transaminase elevations and risk of severe hepatocellular toxicity
Slight reduction in BP	Need for frequent monitoring of liver function
	Possible drug interaction (CYP3A inhibitors)
	Financial burden